Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
about
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsInflammation as a Driver of Clonal Evolution in Myeloproliferative NeoplasmJanus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisPrimary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
P2860
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@ast
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@en
type
label
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@ast
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@en
prefLabel
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@ast
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@en
P2860
P1433
P1476
Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
@en
P2093
John Mascarenhas
P2860
P304
P356
10.3109/10428194.2015.1004670
P577
2015-01-14T00:00:00Z